Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1.

Women-controlled methods for prevention of male-to-female sexual transmission of HIV-1 are urgently needed. Providing inhibitory concentrations of HIV-1 reverse transcriptase inhibitors to impede the replication of the virus in the female genital tissue offers a mechanism for prophylaxis of HIV-1. To this end, an intravaginal ring device that can provide long duration delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1, was developed utilizing a medical-grade polyether urethane. Monolithic intravaginal rings were fabricated and sustained release with cumulative flux linear with time was demonstrated under sink conditions for a period of 30 days. The release rate was directly proportional to the amount of drug loaded. Another release study conducted for a week utilizing liposome dispersions as sink conditions, to mimic the partitioning of dapivirine into vaginal tissue, also demonstrated release rates constant with time. These results qualify polyether urethanes for development of intravaginal rings for sustained delivery of microbicidal agents.

[1]  Joseph P. Romano,et al.  Sustained delivery of microbicide dapivirine using intra-vaginal rings: an independent clinical assessment of safety and drug delivery in women. , 2007 .

[2]  H. Vromans,et al.  In vitro release properties of etonogestrel and ethinyl estradiol from a contraceptive vaginal ring. , 2002, International journal of pharmaceutics.

[3]  Michael A. Parniak,et al.  A Tight-Binding Mode of Inhibition Is Essential for Anti-Human Immunodeficiency Virus Type 1 Virucidal Activity of Nonnucleoside Reverse Transcriptase Inhibitors , 2002, Antimicrobial Agents and Chemotherapy.

[4]  A. Karara,et al.  Polyether polyurethane delivery systems. I. Evaluation of monolithic systems for N6-(Δ2-isopentenyl)adenosine , 1988 .

[5]  I. Fraser,et al.  Vaginal ring delivery of hormone replacement therapy – a review , 2003, Expert opinion on pharmacotherapy.

[6]  M. Stjernquist,et al.  A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. , 1996, American journal of obstetrics and gynecology.

[7]  A. Woolfson,et al.  Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. , 2006, International journal of pharmaceutics.

[8]  F. Roumen.  Contraceptive efficacy and tolerability with a novel combined contraceptive vaginal ring, NuvaRing , 2002, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[9]  R. Sitruk-Ware,et al.  New delivery systems in contraception: vaginal rings. , 2004, American journal of obstetrics and gynecology.

[10]  M. Lúcio,et al.  Partition and location of nimesulide in EPC liposomes: a spectrophotometric and fluorescence study , 2003, Analytical and bioanalytical chemistry.

[11]  F. Uckun,et al.  Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. , 2006, The Journal of antimicrobial chemotherapy.

[12]  C. Watts,et al.  The impact of microbicides on HIV and STD transmission: model projections , 2001 .

[13]  K. Kataoka,et al.  Novel design of microreservoir-dispersed matrices for drug delivery formulations: Regulative drug release from poly(ethylene oxide)- and poly(tetramethylene oxide)-based segmented polyurethanes , 1987 .

[14]  Mukul Singh,et al.  Development of vaginal rings for sustained release of nonhormonal contraceptives and anti-HIV agents. , 2007, Contraception.

[15]  D. Mishell,et al.  The effect of an oral contraceptive on tests of thyroid function. , 1969, Fertility and sterility.

[16]  A. Woolfson,et al.  Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. , 2005, The Journal of antimicrobial chemotherapy.

[17]  Y. Chien,et al.  Solution-solubility dependency of controlled release of drug from polymer matrix: mathematical analysis. , 1975, Journal of pharmaceutical sciences.

[18]  T. Higuchi.  MECHANISM OF SUSTAINED-ACTION MEDICATION. THEORETICAL ANALYSIS OF RATE OF RELEASE OF SOLID DRUGS DISPERSED IN SOLID MATRICES. , 1963, Journal of pharmaceutical sciences.

[19]  D. Lowry,et al.  Potential use of vaginal rings for prevention of heterosexual transmission of HIV , 2006 .

[20]  D. Lowe,et al.  Preliminary report of unexpected local reactions to a progestogen-releasing contraceptive vaginal ring. , 1993, European journal of obstetrics, gynecology, and reproductive biology.

[21]  James M. Anderson,et al.  Polyurethane Elastomer Biostability , 1995, Journal of biomaterials applications.

[22]  M Szycher,et al.  Biostability of Polyurethane Elastomers: A Critical Review , 1988, Journal of biomaterials applications.

[23]  F. Roumen.  Contraceptive efficacy and tolerability with a novel combined contraceptive vaginal ring, NuvaRing. , 2002, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[24]  B. Auvert,et al.  Why do young women have a much higher prevalence of HIV than young men? A study in Kisumu, Kenya and Ndola, Zambia , 2001, AIDS.

[25]  A. Stone.  Microbicides: a new approach to preventing HIV and other sexually transmitted infections , 2002, Nature Reviews Drug Discovery.

[26]  K. Malcolm,et al.  In vitro release of nonoxynol-9 from silicone matrix intravaginal rings. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[27]  M. Pulat,et al.  The release of bovine serum albumin from polyurethane based hydrophilic and hydrophobic disks and microbiological interactions. , 2006, Bio-medical materials and engineering.

[28]  Paul J Lewi,et al.  Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability. , 2005, Journal of medicinal chemistry.

[29]  I. Fraser,et al.  A randomized comparison of the effects on vaginal and cervical epithelium of a placebo vaginal ring with non-use of a ring. , 2000, Contraception.

[30]  H. M. Vinkers,et al.  Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. , 2004, Journal of medicinal chemistry.

[31]  S. Ballagh.  Vaginal ring hormone delivery systems in contraception and menopause. , 2001, Clinical obstetrics and gynecology.

[32]  K. Kataoka,et al.  Novel Design of Microreservoir-Dispersed Matrices for Drug Delivery Formulations: Drug Release from Polybutadiene- and Poly (ethylene oxide)-Based Segmented Polyurethanes in Relation to Their Microdomain Structures , 1988 .

[33]  K. Sreenivasan.  Effect of blending methyl β-cyclodextrin on the release of hydrophobic hydrocortisone into water from polyurethane , 2001 .

[34]  A. Faúndes,et al.  Pros and cons of vaginal rings for contraceptive hormone delivery , 2004 .

[35]  N. R. de Melo,et al.  Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial. , 2005, Human reproduction.

[36]  F. Ahsan,et al.  The vagina as a route for systemic drug delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[37]  K. Kataoka,et al.  Drug release from monolithic devices of segmented polyether‐poly(urethane‐urea)s having both hydrophobic and hydrophilic soft segments , 1986 .

[38]  NN Sarkar,et al.  The combined contraceptive vaginal device (NuvaRing®): A comprehensive review , 2005, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[39]  N. Muhammad,et al.  Evaluation and Selection of Bio-relevant Dissolution Media for a Poorly Water-Soluble New Chemical Entity , 2001, Pharmaceutical development and technology.

[40]  E. Touitou,et al.  The release mechanism of drags from polyurethane transdermal delivery systems , 1984 .

[41]  D. Machin,et al.  Coping with extra Poisson variability in the analysis of factors influencing vaginal ring expulsions. , 1991, Statistics in medicine.

[42]  R. Macdonald,et al.  Small-volume extrusion apparatus for preparation of large, unilamellar vesicles. , 1991, Biochimica et biophysica acta.

[43]  B. O. Juliano,et al.  Rice Quality, Studies on Physicochemical Properties of Rice , 1964 .